eNewsroom for: John Rothman

Update Pharmaceutical company, Inc. is a clinical-stage small molecule company focused on developing overlooked or underutilized anti-cancer drugs. Our lead compound UPI-928 was originally developed more than 20 years ago. It has demonstrated clinical activity and good tolerability in acute myeloid leukemia (AML) and other oncology indications including refractory breast cancer, myeloma, and ovarian cancer.

News from John Rothman:

Update Pharma to Present at the 15th Annual Rodman & Renshaw Global Investment Conference

RENO, Nev., Sept. 6, 2013 /PRNewswire/ — Update Pharma Inc., today announced it will be featured as a presenting company at the 15thAnnual Rodman & Renshaw Global Investment Conference on September 10, 2013 at 3:15 pm in room 7-03 of the Millennium Hotel.  The presentation will be webcast…

Acute Myeloid Leukemia (AML) Therapeutics Pipeline Poised to Grow with Update Pharma Inc.'s Rediscovery of UPI-928

Update to deliver "Re-Discovering UPI-928" presentation at the 3rd World Conference on Cancer Science and Therapy on October 21 in San Francisco RENO, Nev., Aug. 13, 2013 /PRNewswire/ — Update Pharma, Inc. ("Update") announced that the company will make an oral presen…